Ali Raza holds up a tiny capsule no bigger than a vitamin pill, but inside lies a folded polymer film programmed to unfold in the human stomach like a miniature origami device—delivering antibiotics exactly where they’re needed for up to two days. At UiT The Arctic University of Norway in Tromsø, Raza and his team have engineered a breakthrough medical device that could transform how we treat Helicobacter pylori, a stubborn bacterium responsible for millions of stomach ulcers and a leading cause of gastric cancer worldwide. Between 50% and 100% of people in regions with limited access to clean water carry this infection, making effective, accessible treatment a global health imperative.
Current treatments rely on multiple antibiotics taken over a week or more, often causing severe side effects, disrupting the gut microbiome, and increasing the risk of antimicrobial resistance—a growing crisis that threatens modern medicine. The new unfolding capsule offers a smarter alternative: instead of flooding the body with drugs, it releases ciprofloxacin directly in the stomach over 48 hours, maximizing efficacy while minimizing collateral damage. The device is made from a blend of alginate, a natural polymer derived from algae, and a synthetic polymer, shaped into a film that unfolds in stomach acid and remains trapped in the organ thanks to its size—too large to pass through the pyloric sphincter.
In lab tests, the hydrogel films withstood the stomach’s churning motions for at least two days, steadily dispensing antibiotics right at the infection site. Crucially, safety tests on human cells showed over 90% cell survival across various concentrations, a promising sign that the material is biocompatible. "This property lets the films stay in the stomach for a long time so that they can release the antibiotics directly to the infection site," Raza explains. The research, published in Carbohydrate Polymer Technologies and Applications, marks a significant leap in targeted drug delivery—one that could reduce antibiotic use, improve patient compliance, and lower the risk of resistance.
While clinical trials in humans are still ahead, the implications are already clear. For patients in low-resource settings, where H. pylori prevalence is highest, a longer-acting, safer, and more precise treatment could mean fewer missed workdays, fewer complications, and fewer deaths from preventable disease. The team is now refining the system to ensure optimal dosing and long-term safety. As antibiotic resistance tightens its grip on global health, innovations like this offer not just hope, but a tangible path forward—proving that sometimes, the most powerful medicine comes in the smallest, smartest packages.